About Ind Swift
Ind Swift is a company based in Chandigarh (India) founded in 1995. The company has 1,250 employees as of March 31, 2024. Ind Swift offers products and services including APIs, Formulations, CRAMS, and Research Services. Ind Swift operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Chandigarh, India
- Employees 1250 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ind-Swift Laboratories Ltd.
-
Annual Revenue
$65.78 M (USD)-67.13as on Mar 31, 2025
-
Net Profit
$29.26 M (USD)-53.51as on Mar 31, 2025
-
EBITDA
-$2.08 M (USD)-105.78as on Mar 31, 2025
-
Latest Funding Round
-
Investors
-
Employee Count
1250
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ind Swift
Ind Swift is a publicly listed company on the NSE with ticker symbol INDSWFTLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ind Swift
Ind Swift offers a comprehensive portfolio of products and services, including APIs, Formulations, CRAMS, and Research Services.
Manufactures high-quality active ingredients for global pharmaceutical use.
Develops and supplies finished pharmaceutical formulations.
Provides contract research and manufacturing for drug development.
Offers process optimization and new product development services.
People of Ind Swift
Unlock access to complete
Unlock access to complete
Funding Insights of Ind Swift
Investments & Acquisitions by Ind Swift
Financial Statements - Ind Swift
Ind Swift Comparisons
Competitors of Ind Swift
Ind Swift operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical and biotechnology company
|
|
| domain | founded_year | HQ Location |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| domain | founded_year | HQ Location |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
APIs, intermediates, and biochemical reagents are developed and manufactured.
|
|
| domain | founded_year | HQ Location |
APIs are developed and manufactured for therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Contract development, manufacturing, and analytical services for APIs are offered.
|
Latest news on Ind Swift
Frequently Asked Questions about Ind Swift
Ind Swift was founded in 1995.
Ind Swift is headquartered in Chandigarh, India.
Gopal Munjal is the current CEO of Ind Swift.
As of Mar 31, 2024, the latest employee count at Ind Swift is 1,250.
Annual revenue of Ind Swift is $65.78M as on Mar 31, 2025.
Ind-Swift Laboratories Ltd. was established in 1995 in Chandigarh, India, focusing on API manufacturing and CRAMS in the pharmaceutical sector. Operations span six manufacturing sites across India and an independent RD center, enabling API development, finished dosage forms, and non-infringing processes. Services include custom synthesis, preclinical supply, process RD, contract manufacturing of HPAPIs, and analytical plus regulatory support. Facilities are approved by FDA, EDQM, TGA, PMDA, KFDA, and other agencies.
Ind Swift's top competitors include Laurus Labs, Symbiotec and Beijing Biostar Technologies.
Ind Swift offers APIs, Formulations, CRAMS, and Research Services.
Yes, Ind Swift is publicly traded on NSE under the ticker symbol INDSWFTLAB.
The ticker symbol of Ind Swift is INDSWFTLAB on NSE.